AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15975493 — intervention group
Group type: COMPARATOR
Intervention: Control (C; 480 mL of a study beverage containing 82 g of carbohydrate, 20 g of protein, and 14 g of fat)
Number of subjects: 43
Study 15975493 — intervention group
Group type: EXPERIMENTAL
Intervention: Control plus 3.5 g each of phenylalanine and leucine (AA)
Number of subjects: 43
Study 15975493 — intervention group
Group type: EXPERIMENTAL
Intervention: Control plus 1000 mg of S. oblonga extract (S)
Number of subjects: 43
Study 15975493 — intervention group
Group type: EXPERIMENTAL
Intervention: Control plus S and AA (SAA)
Number of subjects: 43
Study 11834946 — intervention group
Group type: EXPERIMENTAL
Intervention: ARV therapy (protease inhibitors: ritonavir, nelfinavir, or lopinavir/ritonavir)
Number of subjects: 15
Study 11834946 — intervention group
Group type: EXPERIMENTAL
Intervention: ARV therapy (ritonavir)
Number of subjects: 15
Study 11834946 — intervention group
Group type: COMPARATOR
Intervention: ARV therapy (zidovudine)
Number of subjects: 15
Study 11834946 — intervention group
Group type: EXPERIMENTAL
Intervention: ARV therapy
Number of subjects: 15
Study 10351853 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged-based message intervention
Number of subjects: 527
Study 10351853 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 527
Study 7747844 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl 25 micrograms.h‐1
Number of subjects: 81
Study 7747844 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl 50 micrograms.h‐1
Number of subjects: 81
Study 7747844 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl 75 micrograms.h‐1
Number of subjects: 81
Study 7747844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 2406849 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mg triazolam
Number of subjects: 5
Study 2406849 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg triazolam
Number of subjects: 5
Study 2406849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 6996635 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable heroin
Number of subjects: 96
Study 6996635 — intervention group
Group type: COMPARATOR
Intervention: Oral methadone
Number of subjects: 96
Study 6996635 — intervention group
Group type: COMPARATOR
Intervention: Refusal to prescribe heroin
Number of subjects: 96
Study 30578850 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visitation program with obesity prevention
Number of subjects: 300
Study 30578850 — intervention group
Group type: COMPARATOR
Intervention: Standard home visitation program
Number of subjects: 300
Study 28793993 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurolidine-citrate-heparin lock
Number of subjects: 41
Study 28793993 — intervention group
Group type: COMPARATOR
Intervention: Heparin 100 IE/mL
Number of subjects: 41
Study 25749825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal liposomal cytarabine (50 mg: 6/8 injections)
Number of subjects: 145
Study 25749825 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal triple therapy (methotrexate/cytarabine/prednisone: 12 injections)
Number of subjects: 145
Study 25749825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal liposomal cytarabine (50 mg)
Number of subjects: 145
Study 25749825 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal triple therapy
Number of subjects: 145
Study 25749825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal liposomal cytarabine
Number of subjects: 145
Study 23406078 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg intravenous hydromorphone
Number of subjects: 175
Study 23406078 — intervention group
Group type: COMPARATOR
Intervention: Usual care (any IV opioid as chosen by ED attending)
Number of subjects: 175
Study 21211865 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy Follow‐Up (PFU) and health education
Number of subjects: 87
Study 21211865 — intervention group
Group type: COMPARATOR
Intervention: Health education only
Number of subjects: 87
Study 18810305 — intervention group
Group type: EXPERIMENTAL
Intervention: Lectures and peer coaching
Number of subjects: 0
Study 16083782 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 microg of oral roflumilast
Number of subjects: 23
Study 16083782 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg of oral roflumilast
Number of subjects: 23
Study 16083782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 12218518 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia with bupivacaine and fentanyl
Number of subjects: 64
Study 12218518 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia with morphine
Number of subjects: 64
Study 12218518 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study 10504889 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifting at slowest speed
Number of subjects: 0
Study 10504889 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifting at slow speed
Number of subjects: 0
Study 10504889 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifting at normal speed
Number of subjects: 0
Study 10504889 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifting at fast speed
Number of subjects: 0
Study 10504889 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifting at fastest speed
Number of subjects: 0
Study 8576484 — intervention group
Group type: EXPERIMENTAL
Intervention: MR images (T1WFS and fast STIR)
Number of subjects: 39
Study 8576484 — intervention group
Group type: COMPARATOR
Intervention: CT images
Number of subjects: 39
Study 8576484 — intervention group
Group type: EXPERIMENTAL
Intervention: T1WFS and fast STIR images
Number of subjects: 39
Study 1789393 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 0
Study 1789393 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 6752250 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy (weekly 30-50 minutes sessions of interpersonal psychotherapy)
Number of subjects: 18
Study 6752250 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (random assignment to either alprazolam, imipramine, or pill-placebo for six weeks)
Number of subjects: 18
Study 6752250 — intervention group
Group type: EXPERIMENTAL
Intervention: Community publicity regarding psychotherapy treatment program
Number of subjects: 18
Study 6752250 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate referrals for diagnostic reasons
Number of subjects: 18
Study 29723080 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic Body Awareness Therapy (BBAT)
Number of subjects: 41
Study 28027282 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin pretreatment (20 mg/kg) with ceftriaxone
Number of subjects: 40
Study 28027282 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone alone
Number of subjects: 40
Study 26215900 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-SNAG
Number of subjects: 32
Study 26215900 — intervention group
Group type: COMPARATOR
Intervention: Sham-SNAG
Number of subjects: 32
Study 23965805 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 0
Study 20418510 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 100 mg once daily
Number of subjects: 33
Study 20418510 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 150 mg once daily
Number of subjects: 33
Study 20418510 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 200 mg once daily
Number of subjects: 33
Study 20418510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 20418510 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (all doses)
Number of subjects: 33
Study 19717248 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (n=51)
Number of subjects: 100
Study 19717248 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=49)
Number of subjects: 100
Study 17244834 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with contextualized intervention strategy (reinforced counseling, improved communication, decentralization of treatment, choice of DOT supporter, reinforcement of supervision activities)
Number of subjects: 1522
Study 17244834 — intervention group
Group type: COMPARATOR
Intervention: Control group with usual TB control program procedures
Number of subjects: 1522
Study 17244834 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 1522
Study 17244834 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1522
Study 15717874 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp70
Number of subjects: 22
Study 15717874 — intervention group
Group type: COMPARATOR
Intervention: BIAsp30
Number of subjects: 22
Study 11838624 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (50 mg/day)
Number of subjects: 76
Study 11838624 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day)
Number of subjects: 76
Study 11838624 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg/day)
Number of subjects: 76
Study 10530410 — intervention group
Group type: EXPERIMENTAL
Intervention: Large hospitals
Number of subjects: 432
Study 10530410 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate hospitals
Number of subjects: 432
Study 10530410 — intervention group
Group type: EXPERIMENTAL
Intervention: Small hospitals
Number of subjects: 432
Study 10530410 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged up to 70 years
Number of subjects: 432
Study 10530410 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients older than 70 years
Number of subjects: 432
Study 7722161 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-targeted educational program on inhaled therapy (45 minutes, one-on-two teaching sessions)
Number of subjects: 50
Study 7722161 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study 2031818 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspired fractional oxygen concentration (FIO2) of 0.5
Number of subjects: 63
Study 2031818 — intervention group
Group type: COMPARATOR
Intervention: Inspired fractional oxygen concentration (FIO2) of 0.33
Number of subjects: 63
Study 7181048 — intervention group
Group type: EXPERIMENTAL
Intervention: Preseasonal hyposensitization
Number of subjects: 0
Study 7181048 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent perennial treatment
Number of subjects: 0
Study 7181048 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal IgE response
Number of subjects: 0
Study 7181048 — intervention group
Group type: EXPERIMENTAL
Intervention: One year after the end of hyposensitization
Number of subjects: 0
Study 31035775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 40
Study 31035775 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 40
Study 30380145 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic spleen-preserving splenic hilar lymphadenectomy (LSPL)
Number of subjects: 222
Study 30380145 — intervention group
Group type: COMPARATOR
Intervention: Open spleen-preserving splenic hilar lymphadenectomy (OSPL)
Number of subjects: 222
Study 26530478 — intervention group
Group type: EXPERIMENTAL
Intervention: Insorb absorbable staples
Number of subjects: 60
Study 26530478 — intervention group
Group type: COMPARATOR
Intervention: Absorbable monofilament sutures
Number of subjects: 60
Study 25162603 — intervention group
Group type: EXPERIMENTAL
Intervention: DETERx 40-mg capsules intact
Number of subjects: 44
Study 25162603 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed DETERx (using the most effective method established in vitro)
Number of subjects: 44
Study 25162603 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewed DETERx
Number of subjects: 44
Study 25162603 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone solution
Number of subjects: 44
Study 22330958 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPw-HBV-IPV/Hib vaccine (full-dose, half-dose, one-third dose)
Number of subjects: 312
Study 22330958 — intervention group
Group type: COMPARATOR
Intervention: Control group (DTPw-HBV/Hib and IPV vaccines administered separately)
Number of subjects: 312
Study 21092015 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse telephone follow-up service for 3 months, twice per week for the first month and weekly for the second and third months.
Number of subjects: 61
Study 21092015 — intervention group
Group type: COMPARATOR
Intervention: Control group (no telephone follow-up).
Number of subjects: 61
Study 21092015 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse telephone follow-up service.
Number of subjects: 61
Study 17645249 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment at Ganshu (BL 18), Shenshu (BL 23), Xinshu (BL 15), once daily.
Number of subjects: 60
Study 17645249 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine hydrochloride, 20 mg, once daily (control group).
Number of subjects: 60
Study 17645249 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Acupuncture and Control).
Number of subjects: 60
Study 17532693 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2-releasing suppository
Number of subjects: 29
Study 17532693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 11695209 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total Plus Whitening Toothpaste
Number of subjects: 100
Study 11695209 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest Multi‐Care Advanced Cleaning Toothpaste
Number of subjects: 100
Study 11695209 — intervention group
Group type: COMPARATOR
Intervention: Colgate Winterfresh Gel
Number of subjects: 100
Study 9615508 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses' self-descriptions and perceptions of their role in BCPT
Number of subjects: 50
Study 9615508 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses' perceptions of the role of women in BCPT
Number of subjects: 50
Study 9615508 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethical and social issues raised by the inquiry
Number of subjects: 50
Study 7643191 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate mouthwash
Number of subjects: 3
Study 7643191 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 percent Lidocaine ointment
Number of subjects: 3
Study 7643191 — intervention group
Group type: COMPARATOR
Intervention: Conventional eugenol‐impregnated iodoform gauze
Number of subjects: 3
Study 2696231 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (4 X 0.5 g intravenously)
Number of subjects: 883
Study 2696231 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (2 g intravenously)
Number of subjects: 883
Study 791478 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC (2 mg/kg/day X 10 iv)
Number of subjects: 50
Study 791478 — intervention group
Group type: COMPARATOR
Intervention: BCNU (150 mg/m2 iv) plus vincristine (2 mg/m2 iv on Day 1 only)
Number of subjects: 50
Study 791478 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary therapy after failure to respond to primary therapy
Number of subjects: 50
Study 31909679 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% citric acid (CA) + 1% sodium hypochlorite (NaOCl)
Number of subjects: 0
Study 31909679 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% ethylenediaminetetraacetic acid (EDTA) + 1% sodium hypochlorite (NaOCl)
Number of subjects: 0
Study 31909679 — intervention group
Group type: COMPARATOR
Intervention: 1% sodium hypochlorite (NaOCl)
Number of subjects: 0
Study 31909679 — intervention group
Group type: COMPARATOR
Intervention: 0.9% physiological saline (PS)
Number of subjects: 0
Study 29353709 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenursing services (N=48) - weekly contact via telephone to motivate self-monitoring and healthy lifestyle.
Number of subjects: 94
Study 29353709 — intervention group
Group type: COMPARATOR
Intervention: Standard diabetes advice and care in the clinic (N=46).
Number of subjects: 94
Study 27299859 — intervention group
Group type: EXPERIMENTAL
Intervention: COPERS intervention (cognitive behavioural approaches, delivered over three alternate days with a follow-up session at 2 weeks)
Number of subjects: 703
Study 27299859 — intervention group
Group type: EXPERIMENTAL
Intervention: COPERS intervention
Number of subjects: 703
Study 27299859 — intervention group
Group type: COMPARATOR
Intervention: Usual care and relaxation CD (control)
Number of subjects: 703
Study 24472799 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation using the Symplicity system
Number of subjects: 93
Study 24472799 — intervention group
Group type: EXPERIMENTAL
Intervention: Redo procedure for renal sympathetic denervation
Number of subjects: 93
Study 22465608 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational angiography
Number of subjects: 104
Study 22465608 — intervention group
Group type: COMPARATOR
Intervention: Conventional coronary angiography
Number of subjects: 104
Study 19890370 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/benazepril (5/20 or 10/40 mg daily)
Number of subjects: 259
Study 19890370 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5 or 10 mg daily)
Number of subjects: 259
Study 18332158 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse depression intervention (n = 164)
Number of subjects: 329
Study 18332158 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care (n = 165)
Number of subjects: 329
Study 15776333 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate pre-exercise, orally ingested sodium load (164 mEq Na+) (IPOSL), equivalent to 10 ml per kilogram of body weight.
Number of subjects: 14
Study 15776333 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage (Pl), hypotonic (94 mOsm . kg (‐1)), no-sodium, equivalent to 10 ml . kg (‐1) body weight.
Number of subjects: 14
Study 12589990 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-course training
Number of subjects: 165
Study 12589990 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention group (10+/−3 months after course)
Number of subjects: 165
Study 12589990 — intervention group
Group type: COMPARATOR
Intervention: Pre-course group
Number of subjects: 165
Study 12589990 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-course group
Number of subjects: 165
Study 10333375 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiosurgery
Number of subjects: 0
Study 10333375 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of surgery and radiotherapy
Number of subjects: 0
Study 10333375 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 0
Study 8738619 — intervention group
Group type: EXPERIMENTAL
Intervention: Cernilton
Number of subjects: 89
Study 8738619 — intervention group
Group type: COMPARATOR
Intervention: Tadenan (Control)
Number of subjects: 89
Study 2016227 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose methylphenidate (0.8 mg/kg)
Number of subjects: 96
Study 2016227 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose methylphenidate (0.4 mg/kg)
Number of subjects: 96
Study 2016227 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral parent training plus child self-control instruction
Number of subjects: 96
Study 2016227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 6218649 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropin followed by fenoterol or vice versa
Number of subjects: 22
Study 31570565 — intervention group
Group type: EXPERIMENTAL
Intervention: Energetic self-management program (4-month group intervention)
Number of subjects: 53
Study 31570565 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 53
Study 29412045 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive use for more than 1 year
Number of subjects: 999
Study 29412045 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive use
Number of subjects: 999
Study 26945575 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaminal®
Number of subjects: 90
Study 26945575 — intervention group
Group type: COMPARATOR
Intervention: Flamazine®
Number of subjects: 90
Study 24841099 — intervention group
Group type: EXPERIMENTAL
Intervention: Information confirming preferences
Number of subjects: 0
Study 24841099 — intervention group
Group type: COMPARATOR
Intervention: Information disconfirming preferences
Number of subjects: 0
Study 24841099 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived information quality
Number of subjects: 0
Study 24841099 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive feedback for confirming preferences
Number of subjects: 0
Study 23204156 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut-enriched meat (WM)
Number of subjects: 22
Study 23204156 — intervention group
Group type: COMPARATOR
Intervention: Conventional meat (CM)
Number of subjects: 22
Study 20954968 — intervention group
Group type: EXPERIMENTAL
Intervention: rMenB+OMV
Number of subjects: 147
Study 20954968 — intervention group
Group type: EXPERIMENTAL
Intervention: rMenB
Number of subjects: 147
Study 20954968 — intervention group
Group type: COMPARATOR
Intervention: Single dose at 12 months
Number of subjects: 147
Study 18408362 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (5-30 mg/kg/day)
Number of subjects: 195
Study 18408362 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine (20-50 mg/kg, 5 days per week)
Number of subjects: 195
Study 16029006 — intervention group
Group type: EXPERIMENTAL
Intervention: High vegetable and fruit diet (12.1 servings per day)
Number of subjects: 64
Study 16029006 — intervention group
Group type: COMPARATOR
Intervention: Low vegetable and fruit diet (3.6 servings per day)
Number of subjects: 64
Study 12414883 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 15
Study 12414883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10856311 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen given before ascent
Number of subjects: 18
Study 10856311 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen given after ascent
Number of subjects: 18
Study 10856311 — intervention group
Group type: COMPARATOR
Intervention: Air given before ascent
Number of subjects: 18
Study 10856311 — intervention group
Group type: COMPARATOR
Intervention: Air given after ascent
Number of subjects: 18
Study 9346222 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin/paclitaxel
Number of subjects: 518